Oncothyreon (ONTY) touches a new 52-week high and is up $1.45 to $10.29 after the Seeking Alpha published a favorable article related to the company’s drug for Stage 3 lung cancer, Stimuvax. The author sees a 90 percent + probability of success. Options action in Oncothyreon is heating up as well, with 30,000 calls and 2,620 puts traded in the Seattle, WA biotech. The top trades are part of a spread, in which the investor sold 2,700 Aug 10 calls at $1 and bought 4,615 Feb 15 calls at $2.70. This diagonal spread might be a bet that shares will hold around $10 over the next four weeks and two days, and then rally through the Feb expiration. Separately, an investor paid an average of 2.625 cents per contract for 5000 Feb 15 calls. Feb 14 calls were also bought at 2.625 cents, 5000X today. Aug 9, Aug 11 and Nov 15 call options on ONTY are seeing interest as well. 2,000 Jan 17 calls traded at $1.90 (customer-to-customer), as I was writing this note. Meanwhile, implied volatility in ONTY options is rallying 35 percent to 99.